Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports

05-04-2024 | Rheumatology | Review

Decoding the Intricacies of Statin-Associated Muscle Symptoms

Authors: Tara Fallah Rastegar, Imtiaz Ahmed Khan, Lisa Christopher-Stine

Published in: Current Rheumatology Reports

Login to get access

Abstract

Purpose of Review

Hyperlipidemia is the major cardiovascular morbidity and mortality risk factor. Statins are the first-line treatment for hyperlipidemia. Statin-associated muscle symptoms (SAMS) are the main reason for the discontinuation of statins among patients. The purpose of this review is to guide clinicians to recognize the difference between self-limited and autoimmune statin myopathy in addition to the factors that potentiate them. Finally, treatment strategies will be discussed. This review mostly focuses on new data in the past 3 years.

Recent Findings

Recent findings suggest that SAMS is a complex and multifactorial condition that involves mitochondrial dysfunction, oxidative stress, and immune-mediated mechanisms. Effective management of SAMS requires a thorough evaluation of the patient’s symptoms, risk factors, and medication history, as well as consideration of alternative treatment options.

Summary

While statins are effective in reducing the risk of cardiovascular events, their use is associated with a range of adverse effects, including SAMS.
Literature
1.
2.
Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292(5519):1160–4.PubMedCrossRef
3.
Blais JE, Wei Y, Yap KKW, Alwafi H, Ma TT, Brauer R, et al. Trends in lipid-modifying agent use in 83 countries. Atherosclerosis. 2021;328:44–51.PubMedCrossRef
4.
Guadamuz JS, Shooshtari A, Qato DM. Global, regional and national trends in statin utilisation in high-income and low/middle-income countries, 2015–2020. BMJ Open. 2022;12(9):e061350.PubMedPubMedCentralCrossRef
5.
Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association’s Muscle Safety Expert Panel null. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58-71.PubMedCrossRef
6.
7.
Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J Clin Med. 2019;9(1):22.PubMedPubMedCentralCrossRef
8.
Norata GD, Tibolla G, Catapano AL. Statins and skeletal muscles toxicity: from clinical trials to everyday practice. Pharmacol Res. 2014;88:107–13.PubMedCrossRef
9.
Li JJ, Liu HH, Wu NQ, Yeo KK, Tan K, Ako J, et al. Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects. Expert Opin Drug Metab Toxicol. 2020;16(9):837–51.PubMedCrossRef
10.
Kasaoka S, Todani M, Kaneko T, Kawamura Y, Oda Y, Tsuruta R, et al. Peak value of blood myoglobin predicts acute renal failure induced by rhabdomyolysis. J Crit Care. 2010;25(4):601–4.PubMedCrossRef
11.•
Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200 and 100 kDa proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62(9):2757–66 This study defined the first description of the anti-HMGCR autoantibody.PubMedPubMedCentralCrossRef
12.
Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713–21.PubMedPubMedCentralCrossRef
13.
Guyton JR, Bays HE, Grundy SM, Jacobson TA, The National Lipid Association Statin Intolerance Panel null. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S72-81.PubMedCrossRef
14.
Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472–83.PubMedCrossRef
15.
Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1–23.PubMedPubMedCentralCrossRef
16.
Mancini GBJ, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol. 2016;32(7 Suppl):S35-65.PubMedCrossRef
17.
Sposito AC, Faria Neto JR, de Carvalho LSF, Lorenzatti A, Cafferata A, Elikir G, et al. Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. Curr Med Res Opin. 2017;33(2):239–51.PubMedCrossRef
18.
Roberts CGP, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2007;62(8):879–87.PubMedCrossRef
19.
Karalis DG, Wild RA, Maki KC, Gaskins R, Jacobson TA, Sponseller CA, et al. Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study. J Clin Lipidol. 2016;10(4):833–41.PubMedCrossRef
20.
Brinton EA, Maki KC, Jacobson TA, Sponseller CA, Cohen JD. Metabolic syndrome is associated with muscle symptoms among statin users. J Clin Lipidol. 2016;10(4):1022–9.PubMedCrossRef
21.
Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP, et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol. 2015;15(178):111–6.CrossRef
22.
Robison CD, Bair TL, Horne BD, McCubrey RO, Lappe DL, Muhlestein JB, et al. Hypothyroidism as a risk factor for statin intolerance. J Clin Lipidol. 2014;8(4):401–7.PubMedCrossRef
23.
Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150(12):858–68.PubMedCrossRef
24.•
Muruganandam M, Iqbal A, Akpan EB, Dolomisiewicz AC, Waters YM, Emil NS, et al. Statin-associated immune-mediated necrotizing myositis in Native Americans. Rheumatology (Oxford). 2022;61(12):4855–62 This study is one of several publications highlighting the increased risk of autoimmune statin myopathy in Native American patients.PubMedCrossRef
25.•
Close RM, Close LM, Galdun P, Gerstberger S, Rydberg M, Christopher-Stine L. Potential implications of six American Indian patients with myopathy, statin exposure and anti-HMGCR antibodies. Rheumatology (Oxford). 2021;60(2):692–8 This study is the first report in the medical literature about the potential increased risk of anti-HMGCR myopathy in Native Americans with elevated lipids.PubMedCrossRef
26.
Schwier NC, Cornelio CK, Boylan PM. A systematic review of the drug-drug interaction between statins and colchicine: patient characteristics, etiologies, and clinical management strategies. Pharmacotherapy. 2022;42(4):320–33.PubMedCrossRef
27.
28.
29.
Rosenson RS, Miller K, Bayliss M, Sanchez RJ, Baccara-Dinet MT, Chibedi-De-Roche D, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 2017;31(2):179–86.PubMedPubMedCentralCrossRef
30.
Vinci P, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Mearelli F, et al. Statin-associated myopathy: emphasis on mechanisms and targeted therapy. Int J Mol Sci. 2021;22(21):11687.PubMedPubMedCentralCrossRef
31.
Selva-O’Callaghan A, Alvarado-Cardenas M, Pinal-Fernández I, Trallero-Araguás E, Milisenda JC, Martínez MÁ, et al. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol. 2018;14(3):215–24.PubMedPubMedCentralCrossRef
32.•
Yogev Y, Shorer Z, Koifman A, Wormser O, Drabkin M, Halperin D, et al. Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone. Proc Natl Acad Sci. 2023;120(7):e2217831120 This study shows that mevalonolactone can protect mice from myotoxicity induced by high-dose statin. This could be applicable in some anti-HMGCR autoantibody positive patients.PubMedPubMedCentralCrossRef
33.
Mollazadeh H, Tavana E, Fanni G, Bo S, Banach M, Pirro M, et al. Effects of statins on mitochondrial pathways. J Cachexia Sarcopenia Muscle. 2021;12(2):237–51.PubMedPubMedCentralCrossRef
34.
Liu M, Fan F, Zhang Y, Li J. The association of GATM polymorphism with statin-induced myopathy: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2021;77(3):349–57.PubMedCrossRef
35.
Davies JT, Delfino SF, Feinberg CE, Johnson MF, Nappi VL, Olinger JT, et al. Current and emerging uses of statins in clinical therapeutics: a review. Lipid Insights. 2016;14(9):13–29.
36.
Xiang Q, Chen SQ, Ma LY, Hu K, Zhang Z, Mu GY, et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J. 2018;18(6):721–9.PubMedCrossRef
37.
Balasubramanian R, Maideen NMP. HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters-an overview. Curr Drug Metab. 2021;22(5):328–41.PubMed
38.
Shahrure ZM, Irshaid YM, Mustafa KN, Abujbara MA, Al Shhab M, El-Khateeb MS, et al. SLCO1B1 gene polymorphisms (rs2306283 and rs4149056) and statin-induced myopathy in Jordanian diabetics. Curr Rev Clin Exp Pharmacol. 2021;16(3):281–8.PubMedCrossRef
39.
Xiang Q, Zhang XD, Mu GY, Wang Z, Liu ZY, Xie QF, et al. Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis. Eur J Clin Pharmacol. 2021;77(4):569–81.PubMedCrossRef
40.
Turongkaravee S, Jittikoon J, Lukkunaprasit T, Sangroongruangsri S, Chaikledkaew U, Thakkinstian A. A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy. Pharmacogenomics J. 2021;21(3):296–307.PubMedPubMedCentralCrossRef
41.
42.
Selva-O’Callaghan A, Alvarado-Cardenas M, Marin A, Pinal-Fernandez I. Statins and myositis: the role of anti-HMGCR antibodies. Expert Rev Clin Immunol. 2015;11(12):1277–9.PubMedCrossRef
43.
Chung T, Christopher-Stine L, Paik JJ, Corse A, Mammen AL. The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. Muscle Nerve. 2015;52(2):189–95.PubMedPubMedCentralCrossRef
44.
45.
Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468–95.PubMedCrossRef
46.
Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14.PubMedCrossRef
47.
Mueller AM, Liakoni E, Schneider C, Burkard T, Jick SS, Krähenbühl S, et al. The risk of muscular events among new users of hydrophilic and lipophilic statins: an observational cohort study. J Gen Intern Med. 2021;36(9):2639–47.PubMedPubMedCentralCrossRef
48.
Lo YC, Lin SY, Ulziijargal E, Chen SY, Chien RC, Tzou YJ, et al. Comparative study of contents of several bioactive components in fruiting bodies and mycelia of culinary-medicinal mushrooms. Int J Med Mushrooms. 2012;14(4):357–63.PubMedCrossRef
49.
Klimek M, Wang S, Ogunkanmi A. Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. P T. 2009;34(6):313–27.PubMedPubMedCentral
50.
Jeng KC, Chen CS, Fang YP, Hou RCW, Chen YS. Effect of microbial fermentation on content of statin, GABA, and polyphenols in Pu-Erh tea. J Agric Food Chem. 2007;55(21):8787–92.PubMedCrossRef
51.
Adler B, Christopher-Stine L, Tiniakou E. Mushroom supplements triggering a flare of HMGCR immune mediated necrotising myopathy. BMJ Case Rep. 2022;15(5):e248880.PubMedPubMedCentralCrossRef
52. •
Mohassel P, Landon-Cardinal O, Foley AR, Donkervoort S, Pak KS, Wahl C, et al. Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy. Neurol Neuroimmunol Neuroinflamm. 2018;6(1):e523 This study reminds clinicians that children (and possibly some young adults) with suspected muscular dystrophy and very high CK levels should be screened for anti-HMGCR autoantibodies.PubMedPubMedCentralCrossRef
53.
Yaworski AM, Blyumin M, Chang T, Mammen AL, Greene M. Necrotizing myopathy with elevated anti-HMGCR antibodies following exposure to the supplement Bacopa. Muscle Nerve. 2023;67(2):E1-3.PubMedCrossRef
54.
Wei H, Xin X, Zhang J, Xie Q, Naveed M, Kaiyan C, et al. Effects of coenzyme Q10 supplementation on statin-induced myopathy: a meta-analysis of randomized controlled trials. Ir J Med Sci. 2022;191(2):719–25.PubMedCrossRef
55.
Hou Q, Pang C, Chen Y. Association between vitamin D and statin-related myopathy: a meta-analysis. Am J Cardiovasc Drugs. 2022;22(2):183–93.PubMedCrossRef
56.
Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis. 2011;215(1):23–9.PubMedCrossRef
57.
Hlatky MA, Gonzalez PE, Manson JE, Buring JE, Lee IM, Cook NR, et al. Statin-associated muscle symptoms among new statin users randomly assigned to vitamin D or placebo. JAMA Cardiol. 2023;8(1):74–80.PubMedCrossRef
58.
Zabihi M, Askarian F, Hekmatimoghaddam S, Rashidi Nooshabadi M, Zabihi MS, Mousavinasab SR. Ascorbic acid significantly decreases creatine kinase plasma levels in an animal model of statin/fibrate-induced myopathy. Adv Pharmacol Pharm Sci. 2021;2021:5539595.PubMedPubMedCentral
59.
Krishna Mohan GV, Chenna VSH, Tirumandyam G, Mian AR, Rashid A, Saleem F. Efficacy and safety of bempedoic acid to prevent cardiovascular events in individuals at risk of cardiovascular diseases: a meta-analysis of randomized-control trials. Cureus. 15(5):e38662
60.
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353–64.PubMedCrossRef
61.
Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662.PubMedPubMedCentralCrossRef
62.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):3168–209.PubMedCrossRef
63. •
Tiniakou E, Rivera E, Mammen AL, Christopher-Stine L. Use of proprotein convertase subtilisin/kexin type 9 inhibitors in statin-associated immune-mediated necrotizing myopathy: a case series. Arthritis Rheumatol. 2019;71(10):1723–6 PCSK9 inhibitors appear to be a safe non-statin alternative treatment for lipid lowering in patients with anti-HMGCR autoantibodies and persistent hypercholesterolemia.PubMedCrossRef
64.
Parker BA, Augeri AL, Capizzi JA, Ballard KD, Troyanos C, Baggish AL, et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol. 2012;109(2):282–7.PubMedCrossRef
65.
Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 1997;46(10):1206–10.PubMedCrossRef
66.
Chung HR, Vakil M, Munroe M, Parikh A, Meador BM, Wu PT, et al. The impact of exercise on statin-associated skeletal muscle myopathy. PLoS ONE. 2016;11(12):e0168065.PubMedPubMedCentralCrossRef
67.
Allard NAE, Janssen L, Lagerwaard B, Nuijten MAH, Bongers CCWG, Rodenburg RJ, et al. Prolonged moderate-intensity exercise does not increase muscle injury markers in symptomatic or asymptomatic statin users. J Am Coll Cardiol. 2023;81(14):1353–64.PubMedCrossRef
Metadata
Title
Decoding the Intricacies of Statin-Associated Muscle Symptoms
Authors
Tara Fallah Rastegar
Imtiaz Ahmed Khan
Lisa Christopher-Stine
Publication date
05-04-2024
Publisher
Springer US
Published in
Current Rheumatology Reports
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-024-01143-y

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits